Introduction of a disulfide bond in the alpha 1 domain of the H-2Kb molecule confers immunogenicity to the transfected RMA-S tumors.
The use of major histocompatibility complex class I genes is an emerging approach for the immunotherapy of human cancer. The conformational stability of class I molecules is important for their immunologic recognition. We have engineered a disulfide bond in the alpha 1 domain of a murine class I molecule, Kb. The expression of the engineered, but not the wild-type, Kb molecules conferred immunogenicity to a nonimmunogenic and antigen presentation-defective tumor cell line, RMA-S. Mice that rejected the engineered Kb-transfected RMA-S cells developed a long-lived antitumor immune response. These data indicate the possibility of genetically engineering class I molecules to improve their therapeutic potential.
Kesari
K V
KV
Howard Hughes Medical Institute, Rockefeller University, New York, New York 10021.
Geliebter
J
J
D000818:Animals; D006084:Graft Rejection / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000737:chemistry* / Q000276:immunology* / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000517:prevention & control; D017433:Protein Structure, Secondary; D013329:Structure-Activity Relationship; D014162:Transfection; D014181:Transplantation Immunology; D014407:Tumor Cells, Cultured
D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I